1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014

Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014" provides data on the Gram-Negative Bacterial Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gram-Negative Bacterial Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gram-Negative Bacterial Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Gram-Negative Bacterial Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Gram-Negative Bacterial Infections 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Gram-Negative Bacterial Infections Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Gram-Negative Bacterial Infections 37
Nov 05, 2014: The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria 37
Oct 09, 2014: Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens 38
Sep 08, 2014: Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens 39
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
GlaxoSmithKline plc 40
Clinical Trial Overview of GlaxoSmithKline plc 40
Sanofi 51
Clinical Trial Overview of Sanofi 51
Novartis AG 58
Clinical Trial Overview of Novartis AG 58
Merck and Co., Inc. 61
Clinical Trial Overview of Merck and Co., Inc. 61
Gilead Sciences, Inc. 63
Clinical Trial Overview of Gilead Sciences, Inc. 63
AstraZeneca PLC 65
Clinical Trial Overview of AstraZeneca PLC 65
Prokarium Ltd. 67
Clinical Trial Overview of Prokarium Ltd. 67
Pfizer Inc. 68
Clinical Trial Overview of Pfizer Inc. 68
Actavis plc 69
Clinical Trial Overview of Actavis plc 69
Clinical Trial Overview of Top Institutes / Government 70
The National Institute of Allergy and Infectious Diseases 70
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 70
National Taiwan University Hospital 72
Clinical Trial Overview of National Taiwan University Hospital 72
University of Pittsburgh 74
Clinical Trial Overview of University of Pittsburgh 74
International Vaccine Institute 76
Clinical Trial Overview of International Vaccine Institute 76
Radboud University 77
Clinical Trial Overview of Radboud University 77
University of Oxford 78
Clinical Trial Overview of University of Oxford 78
Centers for Disease Control and Prevention 79
Clinical Trial Overview of Centers for Disease Control and Prevention 79
Tehran University of Medical Sciences 80
Clinical Trial Overview of Tehran University of Medical Sciences 80
Eunice Kennedy Shriver National Institute of Child Health and Human Development 81
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 81
University of California, San Francisco 82
Clinical Trial Overview of University of California, San Francisco 82
Five Key Clinical Profiles 83
Appendix 121
Abbreviations 121
Definitions 121
Research Methodology 122
Secondary Research 122
About GlobalData 123
Contact Us 123
Disclaimer 123
Source 123

List of Tables

Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Gram-Negative Bacterial Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Gram-Negative Bacterial Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gram-Negative Bacterial Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 40
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 51
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 58
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 61
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 63
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 65
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Prokarium Ltd., 2014* 67
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 68
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014* 69
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 70
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 72
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 74
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by International Vaccine Institute, 2014* 76
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014* 77
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014* 78
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 79
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 80
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 81
Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 82

List of Figures

Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 122

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.